* denotes a publication that resulted from CTD2 intra-Network collaborations
Saturated mutagenesis screen showed that p53 missense mutations in the DNA-binding domain exert a dominant-negative effect. This is a primary unit of selection for TP53 missense mutations.
UCSD researchers developed a framework to simulate population dynamics of heterogeneous tumor cells with a reversible mechanism of resistance. The study provides insights to optimal cancer treatment methods and may guide the development of therapeutic strategies to evade drug resistance.
Researchers at the Emory CTD2 Center showed transcription factor, SOX4, knockdown induced WNT5a expression and increased WNT5a expression are associated with decreased invasive ability in bladder cancer cells.
Study reports that the third-generation pan-FGFR inhibitor, TAS-120, overcomes resistance to several FGFR2 mutations; leads to personalized targeted therapy in FGFR-activated intrahepatic cholangiocarcinoma.
Bioinformatic approach, MethylMix analysis, refines nominations for epigenetic driver genes by leveraging quantitative high-throughput proteomic data to select only genes where DNA methylation is predictive of protein abundance.
UCSF scientists demonstrated that neomorphic fusion oncoprotein, CIC-DUX4, controls capicua-regulated transcriptional pathways to promote hallmark features of malignancy like tumor cell survival, growth, and metastasis.
Review on the role of G protein-coupled receptors as part of cancer signaling networks promoting tumor growth, dissemination, and immune evasion in precision oncology and development of cancer immunotherapies.
Study identifies acetylation as a regulatory mechanism leading ribonucleotide reductase activity, an enzyme that catalyzes the de novo synthesis of precursors required for DNA synthesis.
CTD2 scientists show that metformin suppresses the expression of head and neck squamous cell carcinoma (HNSCC) stem cell programs, causes loss of expression of cancer stem cell markers, and promotes terminal differentiation. This study informs the selection of patients at risk of developing HNSCC.